Table 2.
Independent variables associated with mortality at 30 days.
| Variable | OR (95%CI) | P value |
|---|---|---|
| Age > 66 years | 4.961 (3.367–7.307) | 0.001 |
| Chronic heart disease | 1.629 (1.213–2.188) | 0.001 |
| Haematological disease | 1.868 (1.197–2.915) | 0.006 |
| Chronic kidney disease | 2.392 (1.706–3.354) | 0.001 |
| Solid tumour | 1.459 (1.067–1.996) | 0.018 |
| Temperature > 37 °C | 0.716 (0.541–0.947) | 0.019 |
| Oxygen saturation > 94% | 0.490 (0.360–0.667) | 0.001 |
| Creatinine > 0.92 mg/dL | 1.569 (1.134–2.172) | 0.007 |
| CRP > 3.5 mg/dL (p25) | 1.683 (1.118–2.534) | 0.013 |
| CRP > 13.75 mg/dL (p75) | 2.487 (1.689–3.661) | 0.001 |
| Lymphocyte count > 800 cells/mm3 | 0.711 (0.536–0.944) | 0.018 |
| Invasive mechanical ventilation | 1.668 (1.046–2.659) | 0.032 |
| Remdesivir | 0.531 (0.336–0.836) | 0.006 |
| CRP > 3.5 mg/dL (p25) by tocilizumab the first 5 days | 0.682 (0.464–1.002) | 0.052 |
| CRP > 13.75 mg/dL (p25) by dexamethasone the first 5 days | 0.435 (0.247–0.766) | 0.004 |
Variables included in the model: age, sex, co-morbidity (Chronic heart diseases, Diabetes mellitus, Haematological disease, Chronic kidney disease, hypertension, Solid tumour and Chronic respiratory disease); LDH, creatinine, C-reactive protein, and lymphocyte count at admission [C-reactive protein was introduced by percentiles as well as the interactions between each percentile and tocilizumab or dexamethasone administration within the first 5 days (both variables were also individually included)]; Temperature, and Oxygen saturation at admission; And the need of intensive care admission and invasive mechanical ventilation.
CRP, C-reactive protein. LDH, Lactate Dehydrogenase. P25-75, percentile 25–75.